UNIVERSITY OF MINNESOTA
Improving safety and access to immune effector cell therapy with artificial intelligence technology
Improving safety and access to immune effector cell therapy with artificial intelligence technology is a funding opportunity from UNIVERSITY OF MINNESOTA, up to 207895, closing January 31, 2027.
Jan 31, 2027
(184d left)Overview
PROJECT SUMMARY Immune effector cell-associated neurotoxicity syndrome (ICANS) is a cluster of symptoms associated with immunotherapy that did not show up in pre-clinical studies but has been found in 40-90% of the people undergoing immunotherapy as part of cancer treatment. The purpose of ICANS detection and prompt…